Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
May 5, 2026
Reporting period
Not applicable
Filed with the SEC
May 7, 2026
DirectorGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001159036-26-000063
Filed / recorded
May 7, 2026, 11:04 PM UTC
Added to OQRO
Oct 6, 2026, 7:59 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
HALOZYME THERAPEUTICS, INC.
Issuer CIK
1159036
Ticker
HALO
Reporting person
Mahesh Krishnan
Relationship
Director
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
May 5, 2026
Transaction code
A
Shares / units
3,796
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
14,462
Ownership form
Direct
Amendment
No
Footnotes from the filing
Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders.